drugset / Trial / NCT00536653
Changes in Bone Mineral Density and Fracture Risk in Patients Receiving Androgen Deprivation Therapy for Prostate Cancer
Non-randomizedParallel-groupOpen-labelPrevention
Summary
The aim of this study is to determine the long term effects of two types of hormonal treatment for advanced prostate cancer (LHRH agonists and the antiandrogen bicalutamide)on the bone mineral density of patients.
Timeline
- Start
- 1999-10
- Primary completion
- —
- Completion
- 2007-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bicalutamide | Other / unclassified | 150 mg | — |
| Comparator | Goserelin | Other / unclassified | 10.8 mg | — |
| Comparator | Calcium | Small molecule | — | — |
| Comparator | Vitamin D | Other / unclassified | — | — |